US 11,701,366 B2
Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
Kenneth M. Rosen, Milton, MA (US); Steven Wayne Riesinger, Boston, MA (US); Lisa McKerracher, Boston, MA (US); and Lisa Bond Moritz, Burtonsville, MD (US)
Assigned to BioAxone BioSciences, Inc., Boston, MA (US)
Filed by BioAxone BioSciences, Inc., Boston, MA (US)
Filed on Dec. 7, 2020, as Appl. No. 17/114,335.
Application 17/114,335 is a continuation of application No. 16/214,973, filed on Dec. 10, 2018, granted, now 10,857,157, issued on Dec. 8, 2020.
Application 16/214,973 is a continuation of application No. 15/590,815, filed on May 9, 2017, granted, now 10,149,856, issued on Dec. 11, 2018.
Application 15/590,815 is a continuation in part of application No. 15/006,314, filed on Jan. 26, 2016, granted, now 9,687,483, issued on Jun. 27, 2017.
Claims priority of provisional application 62/286,607, filed on Jan. 25, 2016.
Claims priority of provisional application 62/185,857, filed on Jun. 29, 2015.
Claims priority of provisional application 62/107,571, filed on Jan. 26, 2015.
Prior Publication US 2021/0290635 A1, Sep. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/551 (2006.01); A61K 31/4545 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 31/4725 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for treating a patient having a neurological condition, the method comprising:
orally administering a pharmaceutical formulation comprising therapeutically effective amount of a rho kinase inhibitor to the patient, wherein the rho kinase inhibitor is Compound 1, having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein administering the pharmaceutical formulation to the patient results in a reduction of one or more symptoms of the neurological condition, and
wherein the neurological condition is any of cerebral cavernous malformation, cavernous angioma, stroke, cerebral aneurysm, vasospasm, subarachnoid hemorrhage, cavernoma, a mutation in CCM1, a mutation in CCM2, a mutation in CCM3, or combinations thereof.